c-Met/HGFR
Os inibidores de c-Met/HGFR visam o Receptor do Fator de Crescimento de Hepatócitos (c-Met), uma tirosina quinase envolvida em processos celulares como crescimento, motilidade e morfogênese. A sinalização de c-Met está implicada na progressão do câncer, na metástase e na resistência às terapias. Inibir o c-Met pode interromper o crescimento e a disseminação do tumor, tornando esses inibidores valiosos na pesquisa sobre o câncer. Na CymitQuimica, oferecemos inibidores de c-Met/HGFR para apoiar sua pesquisa em oncologia, metástase e terapias contra o câncer.
Foram encontrados 144 produtos de "c-Met/HGFR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
SRI 31215 TFA
CAS:SRI 31215 TFA acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation.Fórmula:C27H34F3N5O3Pureza:98.25% - 99.97%Cor e Forma:SolidPeso molecular:533.6Ref: TM-T5478
1mg40,00€5mg92,00€10mg128,00€25mg248,00€50mg370,00€100mg527,00€200mg713,00€1mL*10mM (DMSO)96,00€Cabozantinib
CAS:Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM).
Fórmula:C28H24FN3O5Pureza:99.68% - 99.88%Cor e Forma:SolidPeso molecular:501.51(Z)-Semaxinib
CAS:(Z)-Semaxinib (SU5416) is a potent and selective VEGFR(Flk-1/KDR) inhibitor (IC50: 1.23 μM), 20-fold more selective for VEGFR over PDGFRβ, no inhibition forFórmula:C15H14N2OPureza:98.82% - ≥95%Cor e Forma:SolidPeso molecular:238.28Ref: TM-T2496
10mg35,00€25mg52,00€50mg79,00€100mg111,00€200mg168,00€500mg330,00€1mL*10mM (DMSO)44,00€Cabozantinib hydrochloride
CAS:Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6Fórmula:C28H25ClFN3O5Pureza:99.97%Cor e Forma:SolidPeso molecular:537.96Ref: TM-T5164
1mg42,00€2mg52,00€5mg65,00€10mg92,00€25mg160,00€50mg235,00€100mg330,00€200mg538,00€500mg860,00€BAY-474
CAS:BAY-474 is an inhibitor of tyrosine-protein kinase c-Met. It acts as an epigenetics probeFórmula:C17H15N5Pureza:98.98%Cor e Forma:SolidPeso molecular:289.33Ref: TM-T7900
1mg35,00€5mg71,00€10mg112,00€25mg203,00€50mg294,00€100mg411,00€200mg553,00€1mL*10mM (DMSO)84,00€Afatinib
CAS:Afatinib (BIBW 2992) is an irreversible and orally EGFR family inhibitor that inhibits EGFR and HER2. Afatinib has antitumor activity. Cost effective and quality assured.Fórmula:C24H25ClFN5O3Pureza:98.56% - 99.9%Cor e Forma:Off-White SolidPeso molecular:485.94Ref: TM-T21312
5mg34,00€10mg49,00€25mg81,00€50mg109,00€100mg137,00€200mg168,00€500mg284,00€1mL*10mM (DMSO)50,00€Amivantamab (Anti-c-MET)
CAS:Amivantamab (JNJ-61186372) is an antibody that recognizes EGFR and MET and has anticancer and antitumor activities.Pureza:97.24% (SEC-HPLC) - >95.0% (SDS-PAGE); 99.74% (SEC-HPLC)Cor e Forma:LiquidPeso molecular:145.88 kDaBafisontamab
CAS:Bafisontamab (EMB-01) is a bispecific antibody that targets EGFR and cMET, displaying antitumor activity [1].Cor e Forma:LiquidDavutamig
CAS:Davutamig (REGN-5093) is a humanized IgG4-kappa, anti-MET monoclonal antibody that binds to two distinct, nonoverlapping epitopes on the MET receptor.Pureza:98%Cor e Forma:LiquidFiclatuzumab
CAS:Ficlatuzumab is a humanized anti-HGF mAb that inhibits c-Met signaling for squamous cell carcinoma treatment.Pureza:95%Cor e Forma:LiquidPeso molecular:145.39 kDaMAPK-IN-2
MAPK-IN-2 (compound 3h) is an efficacious MAPK inhibitor with antineoplastic properties that significantly hinders proliferation across various cancer cellFórmula:C20H11Cl2N3OPureza:98%Cor e Forma:SolidPeso molecular:380.23BMS-754807
CAS:BMS-754807 is an oral IGF-1R/InsR inhibitor with potential anti-cancer properties.Fórmula:C23H24FN9OPureza:99.69% - 99.94%Cor e Forma:SolidPeso molecular:461.49Ref: TM-T2349
1mg50,00€2mg66,00€5mg90,00€10mg158,00€25mg310,00€50mg509,00€100mg732,00€1mL*10mM (DMSO)110,00€AMG-458
CAS:AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.Fórmula:C30H29N5O5Pureza:99.91% - 99.98%Cor e Forma:SolidPeso molecular:539.58SU11274
CAS:SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.Fórmula:C28H30ClN5O4SPureza:98.62% - 99.53%Cor e Forma:Orange PowderPeso molecular:568.09Ref: TM-T6154
1mg44,00€2mg56,00€5mg92,00€10mg142,00€25mg268,00€50mg442,00€100mg652,00€1mL*10mM (DMSO)142,00€T-1840383
CAS:T-1840383 blocks VEGFR-2 and c-Met phosphorylation in endothelial and cancer cells.Fórmula:C30H25ClFN5O4Cor e Forma:SolidPeso molecular:574c-Met-IN-13
CAS:c-Met-IN-13: potent c-Met inhibitor (IC50 2.43 nM), exhibits anti-proliferative, cytotoxic effects; potential cancer therapy.Fórmula:C30H28F2N2O6Cor e Forma:SolidPeso molecular:550.55c-Met-IN-12
CAS:c-Met-IN-12: potent c-Met/AXL/Mer/TYRO3 inhibitor, IC50=10.6 nM, oral, anti-tumor, scaffold for selectivity enhancement.Fórmula:C34H29FN4O4Cor e Forma:SolidPeso molecular:576.62(R)-Afatinib
CAS:(R)-Afatinib: oral ErbB inhibitor (EGFR/HER2), IC50 ≤14 nM. For ESCC, NSCLC, gastric cancer research.Fórmula:C24H25ClFN5O3Cor e Forma:SolidPeso molecular:485.94Dalmelitinib
CAS:Dalmelitinib: oral c-Met kinase inhibitor, IC50 2.9 nM, disrupts MET, AKT, ERK in cancer cells, for NSCLC research.Fórmula:C22H16FN7O2SCor e Forma:SolidPeso molecular:461.47MK-8033 hydrochloride
CAS:MK-8033 hydrochloride is an oral ATP-competitive c-Met/Ron inhibitor (IC50: c-Met 1nM, Ron 7nM), used for various cancers including NSCLC.Fórmula:C25H22ClN5O3SCor e Forma:SolidPeso molecular:507.99
